Erste Asset Management GmbH Invests $1.24 Million in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Erste Asset Management GmbH purchased a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 120,000 shares of the biotechnology company’s stock, valued at approximately $1,243,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after purchasing an additional 134,292 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Enanta Pharmaceuticals by 13.3% in the second quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock worth $958,000 after buying an additional 8,645 shares during the last quarter. FMR LLC boosted its holdings in shares of Enanta Pharmaceuticals by 18.9% during the 3rd quarter. FMR LLC now owns 49,301 shares of the biotechnology company’s stock worth $511,000 after buying an additional 7,839 shares during the period. Cubist Systematic Strategies LLC grew its stake in Enanta Pharmaceuticals by 65.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 18,003 shares during the last quarter. Finally, Walleye Capital LLC lifted its position in Enanta Pharmaceuticals by 96.4% during the 3rd quarter. Walleye Capital LLC now owns 43,899 shares of the biotechnology company’s stock worth $455,000 after acquiring an additional 21,550 shares during the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ:ENTA opened at $8.76 on Wednesday. The business’s fifty day moving average price is $10.72 and its two-hundred day moving average price is $12.18. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $8.00 and a fifty-two week high of $17.80. The stock has a market capitalization of $185.62 million, a price-to-earnings ratio of -1.60 and a beta of 0.49.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. During the same quarter in the prior year, the company earned ($1.33) earnings per share. The business’s revenue was down 22.8% compared to the same quarter last year. Research analysts expect that Enanta Pharmaceuticals, Inc. will post -5.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. JPMorgan Chase & Co. dropped their price target on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 6th. Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. Robert W. Baird dropped their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a research report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Enanta Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $19.50.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.